ENSC
Ensysce Biosciences, Inc.
Key Financials
Net Income
$2.4M
↑ 557.1%
Operating Income
$-10240946
↓ 52.2%
Revenue
$5.1M
↓ 2.8%
EPS (Diluted)
$-3.98
↑ 65.2%
Total Assets
$7.5M
↑ 33.1%
Total Liabilities
$4.6M
↑ 106.0%
Shareholders' Equity
$3.2M
↓ 13.3%
Cash & Equivalents
$4.3M
↑ 23.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-3 | 6/4/2026 | View on SEC |
| 8-K | 5/22/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| S-8 | 4/30/2026 | View on SEC |
| EFFECT | 4/15/2026 | View on SEC |
| CORRESP | 4/14/2026 | View on SEC |
| UPLOAD | 4/13/2026 | View on SEC |
| S-3 | 4/9/2026 | View on SEC |
| 8-K | 4/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ENSC |
| Company Name | Ensysce Biosciences, Inc. |
| CIK | 1716947 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 263-4196 |